Negative NICE Recommendation for Abraxane in Pancreatic Cancer
NICE (the National Institute for Health and Care Excellence) has issued its Final Appraisal Determination (FAD) on Abraxane (paclitaxel formulated as albumin bound nanoparticles; nab-paclitaxel) in combination with gemcitabine, and has not recommended it for use by NHS England for the treatment of metastatic adenocarcinoma of the pancreas.
In addition, an NHS England review of 42 cancer treatments currently available through the Cancer Drugs Fund (CDF) could result in Abraxane being ‘de-listed’, despite being added to the list earlier this year and the All Wales Medicines Strategy Group (AWMSG) recommending it for use. Abraxane in combination with gemcitabine was added to the CDF in March 2014, following support from 70 leading pancreatic cancer specialists to include it on the list. So far over 260 metastatic pancreatic cancer patients have been able to access Abraxane through the CDF.
Professor Will Steward, Professor of Medical Oncology in Leicester, said: “This is very depressing news for patients with metastatic pancreatic cancer who already have very limited treatment options. This negative NICE decision means that hundreds of patients with metastatic pancreatic cancer, who could potentially benefit from Abraxane, will not have access to it. For a cancer which has such poor survival rates, this is a very sad decision by NICE and now leaves clinicians with limited treatment options.”
Ms Alex Ford, Chief Executive of Pancreatic Cancer UK, said: “This is an extremely worrying time for pancreatic cancer patients and their families. The NICE decision and the review by the CDF which could lead to Abraxane being removed from the CDF, is devastating news for patients with metastatic pancreatic cancer who currently have very few treatment options. Pancreatic Cancer UK calls for NICE to reconsider so that metastatic pancreatic cancer patients in England and Wales are able to benefit from this treatment.”
Ali Stunt, Founder and CEO of Pancreatic Cancer Action, said: “We are outraged that the first licensed and clinically effective treatment for pancreatic cancer in over 7 years has not been approved by NICE. Patients with pancreatic cancer already have a very poor prognosis and limited treatment options. Today’s decision is a backward step by NICE and with the ambiguity surrounding the funding of Abraxane on the CDF, this is an extremely anxious time for future patients with metastatic pancreatic cancer.”
Dr Adrian Kilcoyne, Medical Director, Celgene UK & Ireland, said: “It is very disappointing that NICE did not recommend Abraxane despite the fact they recognised that grounds for end of life could be considered. This decision is a serious setback for both clinicians and patients with metastatic pancreatic cancer.”
“In addition, the potential de-listing of Abraxane from the CDF could mean that patients will not be able to access Abraxane on the NHS in England despite the product in combination with gemcitabine being shown to be clinically effective for previously untreated metastatic pancreatic cancer. We urge NHS England to carefully consider this when decisions are finalised in early January as patients have extremely limited treatment options and the prognosis for pancreatic cancer is so poor, a point which NICE themselves acknowledged in the final appraisal determination.”
Related News
-
News PSCI Welcomes Delpharm, Samsung Biologics, and Suven as First Supplier Partners
The pharmaceutical industry continues to evolve with an increasing focus on responsible sourcing, sustainability, and collaboration across the supply chain. Under a new model to recognise suppliers within the pharmaceutical and healthcare industry that... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Eli Lilly's weight loss drugs removed from the FDA's shortage list
The US FDA have recently updated their drug shortage list. The recently released list shows that all dosage forms of Eli Lilly's weight-loss drug Zepbound and their diabetes drug Mounjaro are now available. -
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance